NDAORALCAPSULE
Approved
Oct 1999
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
4/8 — Partial
TIKOSYN (dofetilide) by Pfizer is clinical pharmacology mechanism of action dofetilide shows vaughan williams class iii antiarrhythmic activity. First approved in 1999.
Drug data last refreshed 16h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TIKOSYN (dofetilide) is an oral Class III antiarrhythmic that selectively blocks the rapid component of the delayed rectifier potassium current (IKr), prolonging the action potential duration and effective refractory period. It is indicated for conversion of atrial fibrillation/flutter and maintenance of normal sinus rhythm in patients with structural heart disease or hemodynamic compromise. The drug demonstrates no negative inotropic effects and does not impair cardiac conduction or sinus node function.
$0.79MPart D
LOE ApproachingProduct approaching end-of-life with minimal Part D volume (626 claims in 2023), indicating significant market maturity and likely small, defensive-focused teams.
Mechanism of Action
CLINICAL PHARMACOLOGY Mechanism of Action Dofetilide shows Vaughan Williams Class III antiarrhythmic activity. The mechanism of action is blockade of the cardiac ion channel carrying the rapid component of the delayed rectifier potassium current, I Kr . At concentrations covering several orders of…
Worked on TIKOSYN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.